冠脉支架术后1年以上房颤患者单用DOAC的疗效与安全性
基于韩国国民健康保险数据,纳入4294例冠脉支架术后1年以上并服用DOAC的房颤患者,比较单药治疗与联合抗血小板治疗。倾向评分匹配后,单药组主要缺血终点和全因死亡风险与联合组相似,大出血风险更低,净不良临床事件无显著差异。
要点
- 支架术后1年以上稳定房颤患者,单用DOAC缺血预防效果不劣于联合抗血小板。
- 单药治疗大出血风险更低,主要源于消化道出血减少。
- 净不良临床事件两组无显著差异,支持个体化选择单药策略。
核心结论
- 冠脉支架术后1年以上房颤患者,DOAC单药治疗预防缺血事件效果与联合抗血小板相似,且大出血风险更低。
研究设计与样本
- 基于韩国国民健康保险服务数据的回顾性队列研究,纳入4294例支架术后1年以上服用DOAC的房颤患者,单药组1221例,联合组3073例,采用倾向评分匹配平衡基线协变量。
主要发现
- 94%患者使用药物洗脱支架,中位随访19(7-32)个月。
- 单药组主要缺血终点风险与联合组相似(HR 0.828,95%CI 0.660-1.038)。
- 单药组全因死亡风险与联合组相似(HR 1.076,95%CI 0.895-1.294)。
- 单药组大出血风险更低(HR 0.690,95%CI 0.481-0.989),主要因消化道出血减少(HR 0.562,95%CI 0.358-0.883)。
- 两组净不良临床事件无显著差异。
临床怎么用
- 对于冠脉支架术后1年以上、病情稳定的房颤患者,可考虑单用DOAC替代DOAC联合抗血小板治疗,以降低出血风险而不增加缺血事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Optimal antithrombotic therapy in patients with atrial fibrillation (AF) beyond 1 year after coronary stent implantation has not been well established in the era of direct oral anticoagulant (DOAC). METHODS: Using Korean National Health Insurance Service data, we analysed 4294 patients with AF who were prescribed DOAC beyond 1 year after coronary stent implantation. Subjects were classified into the monotherapy group (DOAC single therapy, n=1221) or the combination therapy group (DOAC with an antiplatelet agent, n=3073). The primary ischaemic endpoint was defined as a composite of cardiovascular death, myocardial infarction, stroke or systemic thromboembolism. The secondary endpoints were all-cause death, major bleeding defined as a bleeding event requiring hospitalisation and net adverse clinical events. Propensity score matching was performed to balance baseline covariates. RESULTS: Among included patients, 94% had drug-eluting coronary stents. During a median follow-up of 19 (7-32) months, the monotherapy group had a similar risk of the primary ischaemic endpoint (HR 0.828, 95% CI 0.660 to 1.038) and all-cause death (HR 1.076, 95% CI 0.895 to 1.294) compared with the combination therapy group. Risk of major bleeding was lower in the monotherapy group (HR 0.690, 95% CI 0.481 to 0.989), which was mostly driven by reduced gastrointestinal bleeding (HR 0.562, 95% CI 0.358 to 0.883). There was no significant difference in net adverse clinical events between the two groups. CONCLUSIONS: DOAC monotherapy showed similar efficacy in preventing ischaemic events and was associated with lower major bleeding events compared with combination therapy in patients with AF beyond 1 year after coronary stent implantation.
引用
- Choi Y, Lee Y, Kim SH, et al. Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation. Heart. 2021. PMID: 33990409. doi:10.1136/heartjnl-2020-318750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。